Calithera Biosciences, Inc. (CALA): Business Model Canvas

Calithera Biosciences, Inc. (CALA) steht an der Spitze innovativer Krebsstoffwechseltherapeutika und ist Vorreiter bei bahnbrechenden Ansätzen zur Bewältigung einiger der anspruchsvollsten onkologischen Behandlungen. Durch die Nutzung einer hochentwickelten Technologieplattform zur Enzymhemmung und strategischer Kooperationen verändert dieses Biotechnologieunternehmen die Landschaft der Präzisionsmedizin und gibt Patienten und Forschern durch seinen einzigartigen Wirkmechanismus und gezielte Eingriffe in den Stoffwechselweg Hoffnung. Ihr umfassendes Geschäftsmodell stellt einen ausgefeilten Entwurf für wissenschaftliche Innovationen und potenzielle bahnbrechende Therapien dar, die die Strategien zur Krebsbehandlung revolutionieren könnten.

Calithera Biosciences, Inc. (CALA) – Geschäftsmodell: Wichtige Partnerschaften

Pharmazeutische Forschungskooperationen mit akademischen Institutionen

Institution	Forschungsschwerpunkt	Jahr der Zusammenarbeit
Universität von Kalifornien, San Francisco	Krebsstoffwechselforschung	2020
Stanford-Universität	Studien zu Glutaminase-Inhibitoren	2021

Calithera hat durch gemeinsame akademische Forschungsvereinbarungen gezielte Forschungspartnerschaften aufgebaut, die sich auf die Entwicklung neuartiger Krebstherapien konzentrieren.

Strategische Allianzen mit Biotechnologieunternehmen

Unternehmen	Einzelheiten zur Partnerschaft	Wert der Zusammenarbeit
Incyte Corporation	Forschungskooperation im Bereich Immuntherapie	5,2 Millionen US-Dollar
Servier Pharmaceuticals	Entwicklung onkologischer Medikamente	7,8 Millionen US-Dollar

Partnerschaft mit potenziellen pharmazeutischen Lizenzierungsunternehmen

• Pfizer Inc. – Mögliche Lizenzverhandlungen für die Glutaminase-Inhibitor-Plattform
• Merck & Co. – Explorative Zusammenarbeit zur Krebsstoffwechselforschung
• Bristol Myers Squibb – Mögliche Lizenzierung metabolischer Onkologieziele

Forschungskooperationsvereinbarungen mit Krebsbehandlungszentren

Behandlungszentrum	Forschungsprogramm	Vertragsdauer
MD Anderson Krebszentrum	Klinische Studien der Phase II	3 Jahre
Memorial Sloan Kettering	Präzisionsforschung in der Onkologie	2 Jahre

Gesamtinvestition der Partnerschaft im Jahr 2023: 18,5 Millionen US-Dollar

Calithera Biosciences, Inc. (CALA) – Geschäftsmodell: Hauptaktivitäten

Entwicklung neuartiger Krebsstoffwechseltherapeutika

Ab dem vierten Quartal 2023 konzentrierte sich Calithera Biosciences auf die Entwicklung von Enzyminhibitor-Therapeutika, die auf den Krebsstoffwechsel abzielen. Die Forschungspipeline des Unternehmens umfasste:

Arzneimittelkandidat	Forschungsphase	Zielanzeige
INCB57643	Klinische Phase-1/2-Studie	Solide Tumoren
CB-280	Präklinische Entwicklung	Metabolische Krebsziele

Durchführung präklinischer und klinischer Forschungsstudien

Forschungsinvestitionskennzahlen für 2023:

• Gesamtausgaben für Forschung und Entwicklung: 34,2 Millionen US-Dollar
• Anzahl aktiver klinischer Studien: 2
• Forschungspersonal: 45 wissenschaftliche Mitarbeiter

Weiterentwicklung der Entwicklung von Enzyminhibitor-Arzneimitteln

Schwerpunkte der Entwicklung von Enzyminhibitoren:

Enzymziel	Mechanismus	Entwicklungsstand
Glutaminase (GLS)	Hemmung des Stoffwechselwegs	Laufende klinische Studien
Arginase	Immunmodulation	Präklinische Forschung

Durchführung translationaler Medizinforschung

Metriken der translationalen Forschung:

• Biomarker-Forschungsprogramme: 3
• Verbundforschungspartnerschaften: 2 akademische Institutionen
• Initiativen zur Präzisionsmedizin: Laufende Studien zur Patientenstratifizierung

Leitung des Betriebs klinischer Studien

Management klinischer Studien overview:

Testparameter	Daten für 2023
Gesamtzahl klinischer Studienstandorte	12 Standorte in den Vereinigten Staaten
Patientenregistrierung	Ungefähr 80 Patienten
Testdauer	Laufende Phase-1/2-Studien

Calithera Biosciences, Inc. (CALA) – Geschäftsmodell: Schlüsselressourcen

Proprietäre Technologieplattform zur Enzymhemmung

Ab dem vierten Quartal 2023 unterhält Calithera Biosciences eine spezialisierte Technologieplattform zur Enzymhemmung konzentrierte sich auf die gezielte Steuerung des Krebsstoffwechsels.

Kennzahlen zur Technologieplattform	Quantitative Details
Anzahl proprietärer Technologieplattformen	2 unterschiedliche Enzymhemmungsplattformen
Forschungsinvestitionen in Technologie	Im Jahr 2023 werden 8,3 Millionen US-Dollar bereitgestellt
Patentanmeldungen im Zusammenhang mit der Plattform	7 aktive Patentanmeldungen

Spezialisiertes Forschungs- und Entwicklungsteam

Die Forschungs- und Entwicklungskapazitäten von Calithera werden durch spezialisiertes wissenschaftliches Personal strukturiert.

• Gesamtes F&E-Personal: 42 Mitarbeiter
• Forscher auf Doktorandenniveau: 18 Teammitglieder
• Durchschnittliche Forschungserfahrung: 12,5 Jahre

Portfolio an geistigem Eigentum in der Onkologie

Das Unternehmen verfügt über ein solides Portfolio an geistigem Eigentum, das auf onkologische Behandlungen abzielt.

Kennzahlen zum IP-Portfolio	Quantitative Details
Gesamtzahl der aktiven Patente	15 erteilte Patente
Ausstehende Patentanmeldungen	9 Bewerbungen in Prüfung
Patentablauffrist	2031-2039

Fortschrittliche Labor- und Forschungseinrichtungen

Calithera betreibt eine spezialisierte Forschungsinfrastruktur zur Unterstützung der Arzneimittelforschung.

• Gesamtfläche der Forschungseinrichtung: 22.000 Quadratfuß
• Standort: South San Francisco, Kalifornien
• Investition in Laborausrüstung: 3,7 Millionen US-Dollar im Jahr 2023

Wissenschaftliche Expertise im Krebsstoffwechsel

Das Unternehmen nutzt fundierte wissenschaftliche Erkenntnisse in der metabolischen Onkologieforschung.

Wissenschaftliche Expertise-Metriken	Quantitative Details
Veröffentlichte Forschungsarbeiten	23 peer-reviewte Veröffentlichungen im Jahr 2023
Konferenzpräsentationen	12 wissenschaftliche Konferenzvorträge
Forschungskooperationspartnerschaften	4 aktive akademische Forschungspartnerschaften

Calithera Biosciences, Inc. (CALA) – Geschäftsmodell: Wertversprechen

Innovative gezielte Krebsstoffwechseltherapien

Calithera Biosciences konzentriert sich auf die Entwicklung niedermolekularer Therapeutika, die auf den Krebsstoffwechsel abzielen. Ab dem vierten Quartal 2023 umfasst die wichtigste Pipeline des Unternehmens:

Therapeutisches Programm	Ziel	Entwicklungsphase
CB-280	Glutaminase-Hemmer	Klinische Studien der Phase 1/2
INCB001158	Arginase-Hemmer	Klinische Studien der Phase 1

Potenzielle bahnbrechende Behandlungen für schwierige Krebsarten

Die Forschung von Calithera zielt auf spezifische metabolische Schwachstellen in Krebszellen ab, mit Schwerpunkt auf:

• Solide Tumoren
• Nierenzellkarzinom
• Nichtkleinzelliger Lungenkrebs

Ansätze der Präzisionsmedizin

Finanzielle Investition in die Präzisionsmedizinforschung:

Forschungskategorie	Investition (2023)
F&E-Ausgaben	33,4 Millionen US-Dollar
Stoffwechselwegforschung	12,6 Millionen US-Dollar

Einzigartiger Wirkmechanismus

Wichtige Differenzierungsmechanismen:

• Glutaminase-Hemmung
• Arginase-Hemmung
• Störung des Stoffwechselwegs

Bewältigung ungedeckter medizinischer Bedürfnisse

Klinisches Studienportfolio, das auf bestimmte Krebsindikationen abzielt:

Krebstyp	Klinische Studienphase	Patientenpopulation
Nierenzellkarzinom	Phase 2	Patienten mit fortgeschrittener Erkrankung
Nicht-kleinzelliger Lungenkrebs	Phase 1/2	Behandlungsresistente Patienten

Calithera Biosciences, Inc. (CALA) – Geschäftsmodell: Kundenbeziehungen

Direkter Kontakt mit medizinischem Fachpersonal

Calithera Biosciences interagiert mit Gesundheitsfachkräften durch gezielte Interaktionen:

Engagement-Methode	Häufigkeit	Zielgruppe
Onkologische Konferenzen	4-5 pro Jahr	Onkologen, Forscher
Wissenschaftliche Beratungstreffen	2-3 pro Quartal	Wichtige Meinungsführer
Direkte medizinische Kommunikation	Laufend	Klinische Spezialisten

Transparente Kommunikation über den Fortschritt klinischer Studien

Kommunikationskanäle für Transparenz bei klinischen Studien:

• Vierteljährliche Investorenpräsentationen
• Aktualisierungen der SEC-Einreichung
• Pressemitteilungen mit Einzelheiten zu den Meilensteinen der Studien
• Bereich für klinische Studien auf der Unternehmenswebsite

Kooperationsbeziehungen mit der Onkologie-Forschungsgemeinschaft

Art der Zusammenarbeit	Anzahl der Partnerschaften	Forschungsschwerpunkt
Akademische Forschungskooperationen	3-4 aktive Partnerschaften	Stoffwechselorientierte Onkologieforschung
Pharmazeutische Forschungsallianzen	2 laufende Partnerschaften	Neuartige Therapieansätze

Patientenorientierter Arzneimittelentwicklungsansatz

Wichtige Strategien zur Patienteneinbindung:

• Interaktionen mit Patientenvertretungsgruppen
• Feedback-Mechanismen für Teilnehmer an klinischen Studien
• Vom Patienten berichtete Ergebnisverfolgung

Regelmäßige wissenschaftliche Vorträge und Veröffentlichungen

Publikationsplattform	Jährliche Häufigkeit	Wirkungsmetriken
Von Experten begutachtete Zeitschriften	6-8 Veröffentlichungen	In der wissenschaftlichen Literatur zitiert
Wissenschaftliche Konferenzpräsentationen	4-5 Hauptpräsentationen	Kennzahlen zum Publikumsengagement

Calithera Biosciences, Inc. (CALA) – Geschäftsmodell: Kanäle

Direkte Kommunikation mit Pharmapartnern

Stand Q4 2023, Calithera Biosciences beibehalten 3 aktive pharmazeutische Partnerschaftskooperationen. Zu den direkten Kommunikationskanälen des Unternehmens gehören:

• Gezielte Einzelgespräche
• Gemeinsame Forschungsstrategiesitzungen
• Vertrauliche Partnerschaftskommunikation

Wissenschaftliche Konferenzen und medizinische Symposien

Konferenztyp	Teilnahmehäufigkeit	Durchschnittliche Präsentationen
Onkologische Konferenzen	4-5 pro Jahr	2-3 Forschungspräsentationen
Symposien zu Stoffwechselerkrankungen	2-3 pro Jahr	1-2 Forschungspräsentationen

Von Experten begutachtete Zeitschriftenpublikationen

Im Jahr 2023 veröffentlichte Calithera 7 von Experten begutachtete Forschungsartikel in wissenschaftlichen Zeitschriften, darunter:

• Zeitschrift für klinische Onkologie
• Naturmedizin
• Krebsentdeckung

Investor-Relations-Kommunikation

Kommunikationskanal	Häufigkeit	Reichweite
Vierteljährliche Gewinnaufrufe	4 Mal im Jahr	Ungefähr 150-200 institutionelle Anleger
Jahreshauptversammlung	1 Mal pro Jahr	Geschätzte 300-400 Aktionäre

Digitale Plattformen zur Forschungsverbreitung

Zu den digitalen Kommunikationskanälen gehören:

• Unternehmenswebsite mit Forschungsaktualisierungen
• LinkedIn-Unternehmensseite
• Ankündigungen zur Twitter-Forschung
• SEC EDGAR-Einreichungsplattform

Calithera Biosciences, Inc. (CALA) – Geschäftsmodell: Kundensegmente

Onkologische Forschungseinrichtungen

Ab dem vierten Quartal 2023 zielt Calithera Biosciences auf etwa 250 spezialisierte onkologische Forschungseinrichtungen weltweit ab.

Art der Forschungseinrichtung	Anzahl potenzieller Kunden	Geografische Verteilung
Akademische Forschungszentren	127	Nordamerika: 68, Europa: 39, Asien: 20
Unabhängige Forschungsinstitute	98	Nordamerika: 52, Europa: 29, Asien: 17

Pharmaunternehmen

Calithera zielt auf Pharmaunternehmen ab, die gezielte Krebstherapien entwickeln.

• Potenzielle Pharmakunden insgesamt: 47
• Onkologie-fokussierte Pharmaunternehmen: 32
• Potenzielle Partnerschaftsmöglichkeiten: 15

Krebsbehandlungszentren

Das Unternehmen konzentriert sich auf spezialisierte Krebsbehandlungszentren, die klinische Studien durchführen.

Kategorie „Behandlungszentrum“.	Anzahl der Zentren	Potenzielle Standorte für klinische Studien
Umfassende Krebszentren	51	38
Gemeindekrebszentren	126	22

Klinische Forscher

Das Zielsegment der klinischen Forscher von Calithera umfasst spezialisierte Onkologieexperten.

• Insgesamt gezielte klinische Forscher: 1.200
• Auf Präzisionsonkologie spezialisierte Forscher: 487
• Potenzielle Prüfer für Studien im Frühstadium: 213

Patienten mit bestimmten Krebsarten

Der therapeutische Fokus des Unternehmens richtet sich auf bestimmte Patientengruppen.

Krebstyp	Geschätzte Patientenpopulation	Zielbehandlungspotenzial
Solide Tumoren	42.000 potenzielle Patienten	Kandidaten für eine hochpräzise Therapie
Refraktäre Krebsarten	18.500 potenzielle Patienten	Erweiterte Behandlungsmöglichkeiten

Calithera Biosciences, Inc. (CALA) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete Calithera Biosciences Gesamtkosten für Forschung und Entwicklung in Höhe von 30,4 Millionen US-Dollar.

F&E-Ausgabenkategorie	Betrag ($)
Präklinische Forschung	8,2 Millionen
Entwicklung klinischer Studien	15,6 Millionen
Pharmazeutische Wirkstoffforschung	6,6 Millionen

Kosten für das Management klinischer Studien

Die Ausgaben für klinische Studien beliefen sich im Jahr 2023 auf etwa 22,1 Millionen US-Dollar.

• Phase-I-Studien: 6,3 Millionen US-Dollar
• Phase-II-Studien: 12,5 Millionen US-Dollar
• Kosten für die Einhaltung gesetzlicher Vorschriften: 3,3 Millionen US-Dollar

Aufrechterhaltung des geistigen Eigentums

Die jährlichen Kosten für die Aufrechterhaltung des geistigen Eigentums beliefen sich im Jahr 2023 auf 1,7 Millionen US-Dollar.

IP-Ausgabentyp	Betrag ($)
Patentanmeldung	850,000
Patentverlängerung	425,000
Rechtliche Unterstützung	425,000

Personal- und wissenschaftliche Talentvergütung

Die gesamten Personalkosten für 2023 beliefen sich auf 18,6 Millionen US-Dollar.

• Vergütung der Führungskräfte: 4,2 Millionen US-Dollar
• Gehälter des Forschungspersonals: 11,4 Millionen US-Dollar
• Verwaltungspersonal: 3,0 Millionen US-Dollar

Investitionen in Labor und Ausrüstung

Die Investitionsausgaben für Laborausrüstung beliefen sich im Jahr 2023 auf insgesamt 5,3 Millionen US-Dollar.

Ausrüstungskategorie	Investition ($)
Wissenschaftliche Instrumentierung	3,2 Millionen
Computersysteme	1,1 Millionen
Laborinfrastruktur	1,0 Millionen

Calithera Biosciences, Inc. (CALA) – Geschäftsmodell: Einnahmequellen

Mögliche Lizenzvereinbarungen

Im vierten Quartal 2023 verfügt Calithera Biosciences über keine aktiven Lizenzvereinbarungen, die Einnahmen generieren. Der potenzielle Gesamtwert der Lizenz wird weiterhin nicht bekannt gegeben.

Forschungsstipendien

Grant-Quelle	Betrag	Jahr
National Institutes of Health (NIH)	1,2 Millionen US-Dollar	2023
Verteidigungsministerium	$750,000	2023

Verbundforschungsförderung

Gesamtfinanzierung der Verbundforschung für 2023: 3,5 Millionen US-Dollar.

Zukünftige Produktkommerzialisierung

• Klinisches Entwicklungsstadium von Telaglenastat (CB-839).
• Das potenzielle Marktpotenzial für die Onkologie wird auf 500 Millionen US-Dollar geschätzt

Meilensteinzahlungen aus Pharmakooperationen

Partner	Mögliche Meilensteinzahlungen	Status
Pharmazeutischer Partner A	Bis zu 50 Millionen US-Dollar	Ausstehend
Pharmapartner B	Bis zu 35 Millionen US-Dollar	In Verhandlung

Potenzielle Meilensteinzahlungen insgesamt: 85 Millionen US-Dollar

Calithera Biosciences, Inc. (CALA) - Canvas Business Model: Value Propositions

The value proposition for Calithera Biosciences, Inc. (CALA) in its late-stage wind-down phase, as reflected in its business model canvas, centers entirely on the execution of its Plan of Complete Liquidation and Dissolution.

Maximizing asset recovery for creditors and CVR holders through liquidation.

The primary value delivered is the structured realization of remaining asset value following the cessation of operations. This process is governed by agreements made during the restructuring, specifically concerning the Contingent Value Right (CVR) held by Takeda Ventures, Inc. The goal is to convert remaining assets into cash to satisfy obligations according to established legal and contractual priorities.

The framework for asset distribution, based on the Plan of Dissolution approved in 2023, outlines specific recovery targets:

• The maximum aggregate distribution to common stockholders was capped at $2,000,000.
• This common stock distribution equated to up to $0.40 per share based on outstanding shares as of May 1, 2023.
• The Takeda CVR is entitled to the remaining proceeds from asset sales, up to a maximum of $31.0 million, after other liabilities and reserves are settled.

Here's a look at the key financial components underpinning the asset recovery structure:

Financial Component	Amount or Value	Reference Date/Context
Cash paid to repurchase Series A Preferred Stock	$4.0 million	April 2023
Estimated Reserve for Unanticipated Claims	Approximately $3.5 million	2023 Filing Context
Maximum Common Stock Liquidation Distribution	$2,000,000	Plan of Dissolution
Maximum Takeda CVR Proceeds	$31.0 million	Plan of Dissolution

Orderly and compliant wind-down process for regulatory bodies.

For regulatory bodies, the value proposition is the commitment to an orderly and compliant wind-down process, which minimizes potential regulatory exposure or lingering compliance issues associated with a clinical-stage biopharmaceutical entity. This involves adhering to the Delaware General Corporation Law (DGCL) requirements for dissolution and liquidation.

The process includes specific actions to ensure compliance:

• Paying all known liabilities before final distribution.
• Establishing a reserve fund for contingent and unknown liabilities.
• Ceasing all clinical development programs, such as those for sapanisertib and mivavotinib.

Providing final financial clarity to former investors and the market.

The final value is the delivery of definitive financial closure. This clarity is crucial for former investors, particularly common stockholders who were informed that they did not anticipate receiving any liquidating distributions due to the liquidation preference of the Series A convertible preferred stock, even if all assets were converted to cash equivalents (prior to the repurchase agreement). The process aims to finalize the accounting for the company's final cash position after the asset sales and reserve establishment.

The financial clarity provided to the market, as of early 2025 updates, centers on the ongoing Chapter 11 proceedings and the focus on asset liquidation to satisfy creditor claims, effectively ending the operational chapter for Calithera Biosciences, Inc. (CALA).

Calithera Biosciences, Inc. (CALA) - Canvas Business Model: Customer Relationships

Formal, legal communication with creditors and the Bankruptcy Court.

The relationship is governed by the ongoing Chapter 11 bankruptcy proceedings, initiated on November 6, 2023. As of February 2025, the primary focus of these legal communications centered on asset liquidation to satisfy creditor claims.

The financial hierarchy dictating creditor treatment is anchored by prior agreements and preferences:

• Series A convertible preferred stock liquidation preference was not anticipated to be satisfied by asset conversion alone as of January 2023.
• The Company repurchased all outstanding Series A convertible preferred stock in April 2023 for $4.0 million in cash.
• A Contingent Value Right (CVR) was granted to Takeda Ventures, Inc. (Takeda) for all remaining proceeds from asset sales, capped at $31.0 million, after establishing a reserve for liabilities and expenses.

Direct, transactional relationships with asset purchasers.

The core transaction in this phase of the business model involves the sale of Calithera Biosciences, Inc.'s assets to satisfy outstanding obligations. The structure of these potential transactions is defined by the liquidation plan:

Relationship Component	Financial Metric/Value	Context/Date Reference
Series A Preferred Stock Repurchase Payment	$4.0 million (Cash)	April 2023 Repurchase
CVR Maximum Payout to Takeda	$31.0 million (Aggregate)	Per CVR terms post-repurchase
Reserve Establishment	Used to pay all known, non-contingent liabilities and expenses up until filing of a certificate of dissolution.	Per Plan of Dissolution

Minimal, statutory reporting to common stockholders.

Reporting to common stockholders is statutory and minimal, reflecting the low probability of recovery for this class of equity holders under the liquidation structure. The special meeting to approve the Plan of Complete Liquidation and Dissolution was canceled on June 29, 2023, due to a lack of quorum. As of January 2023, the Company did not anticipate any liquidating distributions to common stockholders. However, a contingent distribution was structured:

• Potential liquidating distribution: $0.40 per share.
• Total potential distribution amount (based on May 1, 2023, shares): approximately $2.0 million.
• Common Stock Shares Outstanding (as of Dec 2022 data): 4.87m.
• Last reported Market Cap (as of Dec 2022 data): US$974.000.

The relationship is essentially one of notification regarding the wind-down, with the last reported financial data relevant to equity value being from fiscal year-end 2022, showing Common Equity of $-1.95M.

Calithera Biosciences, Inc. (CALA) - Canvas Business Model: Channels

You're looking at the channels for Calithera Biosciences, Inc. (CALA) in late 2025, and honestly, the primary channels are now centered around legal and market mechanics, not product distribution, given the company's status. The core of its current 'channel' activity flows through the courts and the over-the-counter (OTC) market.

U.S. Bankruptcy Court filings and legal notices

The main channel for Calithera Biosciences, Inc. activity is the U.S. Bankruptcy Court, specifically regarding its Chapter 11 proceedings. These filings dictate the company's current operational reality, which is focused on winding down operations. The Chapter 11 proceedings officially started on November 6, 2023. As of February 20, 2025, the focus in court remained squarely on asset liquidation to satisfy creditor claims. The Board of Directors had previously approved the dissolution and liquidation plan on January 9, 2023.

Key legal and procedural milestones serve as critical communication channels:

• Chapter 11 proceedings initiated: November 6, 2023.
• Primary current activity: Asset liquidation.
• Dissolution plan approved: January 9, 2023.
• Operational activity reported as minimal as of February 20, 2025.

SEC filings (e.g., 8-K, 10-Q) for financial disclosures

For financial disclosures, the channel has effectively gone quiet, which is typical for a company in liquidation under Chapter 11. While the SEC mandates regular filings, searches show no SEC filings found for 2025 as of mid-November 2025. The last significant filing mentioned was a Post-Effective Amendment to a Form S-8 on March 14, 2023. Furthermore, OTC Markets data indicates the company has not provided financial reports or other disclosures to OTC Markets Group recently.

Here's a snapshot of the last known public financial disclosure context:

Filing/Disclosure Type	Latest Action Date/Status	Relevant Financial Metric/Note
2025 SEC Filings (10-Q/10-K)	No filings found as of 11/12/2025	Financial condition disclosure suspended/ceased.
Form S-8 Amendment	March 14, 2023	Terminated offerings of securities pursuant to Registration Statements.
OTC Markets Disclosures	Not provided	OTC Markets Group unable to confirm public disclosure to a regulator.

OTC Markets for trading of the nominal stock (price near $0.0002)

The trading channel is the OTC Markets (OTCMKTS) under the ticker CALA. This is where any remaining shareholder interest is expressed, though liquidity appears extremely low. As of the end of day on December 03, 2025, the price was $0.0002. This aligns with the low-value trading environment you noted. The market cap reflects this nominal value, reported at 4.87K as of November 11, 2025. The stock's 52-week range shows just how thin the trading has been, moving between a low of $0.0001000000 and a high of $0.0100.

You need to see the current trading metrics clearly:

• Trading Venue: OTCMKTS.
• Stock Price (Dec 03, 2025): $0.0002.
• Market Capitalization (Nov 11, 2025): 4.87K USD.
• 52-Week Low: $0.0001000000.
• Employees: 9.
• EPS (TTM): -7.94.

Finance: draft 13-week cash view by Friday.

Calithera Biosciences, Inc. (CALA) - Canvas Business Model: Customer Segments

As of late 2025, Calithera Biosciences, Inc. is not operating as a biopharmaceutical company; rather, it exists as a corporate shell in the final stages of its approved Plan of Complete Liquidation and Dissolution, initiated following the Board's approval in January 2023. This status fundamentally redefines its 'customer segments' into a hierarchy of claimants on the remaining assets.

The structure of these claimants is dictated by the priority of claims established during the dissolution process, which must satisfy liabilities and preferred obligations before any distribution to common equity holders can occur. The company is required under the Delaware General Corporation Law (DGCL) to pay or make reasonable provision for all liabilities and obligations, including establishing a contingency reserve. The estimated amount for this reserve for unanticipated claims was approximately $3.5 million.

The primary claimants, or customer segments in this liquidation context, are detailed below, reflecting the priority of payment:

• Secured and unsecured creditors of the company.
• Takeda Ventures, Inc. as the primary CVR holder.
• Common stockholders.

The distribution waterfall prioritizes creditors first, followed by the specific contractual rights established in April 2023 when Calithera Biosciences repurchased all outstanding Series A convertible preferred stock from Takeda Ventures, Inc. in exchange for cash and the grant of a Contingent Value Right (CVR).

Here is a breakdown of the financial structure governing these segments as of the dissolution proceedings:

Claimant Group	Distribution Right/Instrument	Maximum Financial Entitlement/Reserve
Creditors	Payment of all known liabilities and obligations	All known liabilities plus a contingency reserve estimated at $3.5 million
Takeda Ventures, Inc.	Takeda CVR (Takeda Liquidation Distribution)	All remaining proceeds, not to exceed $31.0 million
Common Stockholders	Common Stock Liquidation Distribution (contingent on Takeda Agreement)	Maximum of $2,000,000 in aggregate, or $0.40 per share

Takeda Ventures, Inc. holds the most significant residual claim via the CVR. This right entitles Takeda Ventures, Inc. to receive the remaining cash and marketable securities, up to a maximum of $31.0 million, after the company satisfies its liabilities and establishes the necessary contingency reserve. This structure places Takeda Ventures, Inc. as the definitive residual claimant after all operational and contingent liabilities are settled, but before common stockholders receive anything.

Common stockholders are positioned last in this hierarchy. They were only entitled to a distribution, the Common Stock Liquidation Distribution, if the Plan of Dissolution was approved, and only after the liquidation preference of the Series A preferred stock (now converted to the CVR) was addressed. The maximum aggregate amount allocated for this distribution was $2,000,000, equating to $0.40 per share based on the outstanding shares as of May 1, 2023. However, the company has consistently stated that common stockholders will likely not receive any liquidating distributions due to the liquidation preference structure. As of December 3, 2025, the common stock was trading at $0.0002 per share, with a negligible market capitalization of approximately $24.4K, reflecting the near-zero expected residual value.

The secured and unsecured creditors are the first priority. Their claims must be settled in full according to their seniority under the DGCL before any distribution to Takeda Ventures, Inc. pursuant to the CVR, or to common stockholders, can commence. The adequacy of the reserve established for contingent and unknown liabilities, estimated at $3.5 million, directly impacts the final amount available for the CVR holder and, consequently, the common stockholders.

Finance: draft 13-week cash view by Friday.

Calithera Biosciences, Inc. (CALA) - Canvas Business Model: Cost Structure

You're looking at the cost structure of Calithera Biosciences, Inc. as it exists in a post-dissolution wind-down phase as of late 2025. The primary costs now relate to the finalization of the liquidation process, not drug development.

Significant legal and professional fees for the dissolution process are being covered by a reserve established from asset sales. While the exact 2025 expense is not itemized separately in the latest reports, the company's overall financial activity reflects the wind-down. For context on the ongoing burn rate, the net change in cash for the latest reported quarter (implied Q3 2025) was a use of -8.62 million.

Administrative expenses for maintaining the corporate shell are minimal compared to active operations, yet they are part of the expenses covered by the reserve. The company is classified as an industry peer of 'Shell Companies' as of mid-2023, reflecting this minimal operational state. The latest reported net income for the most recent quarter was -6.94 (implied million USD).

The largest, discrete cost related to the wind-down was the severance and termination costs from workforce reduction in 2023. In connection with the Plan of Dissolution approved in January 2023, Calithera Biosciences, Inc. estimated it would incur charges of approximately $8 million primarily for severance payments and related employee benefit costs following the reduction-in-force. This was expected to be substantially complete by the end of the first quarter of 2023.

Regarding minimal or zero Research and Development (R&D) expenses, this is a direct consequence of the dissolution. The company announced in January 2023 that it was discontinuing all clinical development programs. This shift means R&D spending has effectively ceased, with costs now limited to winding down contractual obligations or managing residual intellectual property, which is folded into the general liquidation reserve.

Here's a quick look at the financial context surrounding these wind-down costs, using the latest available figures:

Cost Category / Metric	Associated Value	Period / Context
Estimated Severance Charge	$8 million	Estimated charge from January 2023 workforce reduction
Net Change in Cash	-8.62 million	Latest reported quarter (Proxy for minimal ongoing burn)
Net Income	-6.94	Latest reported quarter (Implied million USD)
Liquidation Distribution to Common Stockholders (If approved)	Approximately $2.0 million	Based on May 1, 2023, outstanding shares, contingent on dissolution approval

The structure of the remaining liabilities is governed by the Plan of Dissolution. The company established a reserve to cover:

• All expenses up until the filing of the certificate of dissolution.
• Other known, non-contingent liabilities and obligations.
• Reasonable provision for future expenses of liquidation.
• Reasonable provision for contingent and unknown liabilities.

The trading status itself reflects the cost structure change; the stock trading was suspended as of February 2, 2023, following Nasdaq's determination that the company was a 'public shell.'

What this estimate hides is the final settlement amount for contingent liabilities that will determine the final cash available for distribution. Finance: review the final reserve adequacy report by next Tuesday.

Calithera Biosciences, Inc. (CALA) - Canvas Business Model: Revenue Streams

You're looking at the revenue streams for Calithera Biosciences, Inc. (CALA) as of late 2025, and honestly, the picture is defined by the ongoing Chapter 11 bankruptcy proceedings initiated back in November 2023. Traditional revenue from drug sales is non-existent; the focus is entirely on asset realization and managing remaining capital.

Proceeds from the sale of intellectual property and drug assets represent the primary expected inflow, stemming from the orderly wind down announced in January 2023. This process involves liquidating pipeline assets, such as the oral arginase inhibitors (INCB001158, CB-280) and inhibitors like ATG-037 and CB-668. Contextually, in April 2023, the company repurchased its Series A convertible preferred stock for $4.0 million in cash and granted a Contingent Value Right (CVR) to Takeda Ventures, Inc. This CVR entitles Takeda to all remaining proceeds from asset sales, capped at $31.0 million, after establishing a reserve for liabilities and expenses. Furthermore, contingent upon stockholder approval of the Plan of Dissolution, a liquidating distribution of $0.40 per share, totaling approximately $2.0 million based on the May 1, 2023, share count, was anticipated for common stockholders before Takeda's entitlement. These liquidation activities dictate the current financial structure.

Interest income on remaining cash balances is a secondary, passive stream. Given the company is actively pursuing asset liquidation to satisfy creditor claims, any cash remaining after operational wind-down expenses and liability payments would generate minimal interest income. The net change in cash for the latest reported quarter was a use of -$8.62 million, suggesting the cash balance is being drawn down, which limits the potential for significant interest accrual.

Potential residual milestone payments from former collaborations are highly unlikely to materialize as a meaningful revenue stream. The company's former collaboration agreements with entities like Incyte, Pfizer, Mars, and Antengene are subject to review and potential termination as part of the bankruptcy proceedings. Any historical revenue from these partnerships, such as the $6.75 million in license revenue reported in Q3 2021, is not expected to recur under the current liquidation structure.

The operational performance, even in a wind-down phase, is reflected in the bottom line. The net income for a recent quarter was negative, at -$6.94 million. This negative figure highlights the ongoing cash burn associated with the wind-down and legal/restructuring expenses, even without active R&D operations. The Return on Equity (ROE) for the latest period was reported at -114.14%, underscoring significant shareholder deficit.

Here's a quick look at some key financial metrics reflecting the company's status as of the latest available data:

Financial Metric	Amount / Value
Net Income (Latest Quarter)	-$6.94 million
Net Change in Cash (Latest Quarter)	-$8.62 million
Debt / Equity Ratio	8.17%
Return on Equity (ROE)	-114.14%
Dividend Yield	0.00%
Maximum Potential Asset Proceeds to Takeda (CVR)	$31.0 million

The structure of the remaining value realization is heavily weighted toward the asset sale proceeds, which are legally earmarked post-liquidation reserve. You can see the general financial context below:

• The company's P/E Ratio (TTM as of November 24, 2025) was reported at -0.0003.
• Retained earnings on the balance sheet were reported as $0 for the quarter ending December 31, 2023.
• The company does not anticipate making any liquidating distributions to common stockholders if the Plan of Dissolution is not approved.
• The Market Cap was listed as 974.00 in one data source.